● Recruiting

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Condition: Non-Small Cell Lung Cancer (NSCLC) · Colorectal Cancer · Pancreatic Ductal Adenocarcinoma · Sponsor: Revolution Medicines, Inc.

PhasePhase 1/Phase 2

Planned participants534

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.

This description comes directly from the study's public registry record.

Talk to the study team

Revolution Medicines, Inc. · 1-844-2-REVMED · medinfo@revmed.com

Always discuss trial participation with your own doctor first.

Locations (53)

City of Hope	Duarte, California, United States	Withdrawn
UC IRVINE Health	Orange, California, United States	Recruiting
UC Davis Comprehensive Cancer Center	Sacramento, California, United States	Recruiting
Stanford Cancer Institute	Stanford, California, United States	Recruiting
University of Colorado Cancer Center	Aurora, Colorado, United States	Recruiting
Florida Cancer Specialists	Sarasota, Florida, United States	Recruiting
Moffitt Cancer Center and Research Institute	Tampa, Florida, United States	Recruiting
Dana Farber Cancer Institute	Boston, Massachusetts, United States	Recruiting
Henry Ford Cancer	Detroit, Michigan, United States	Withdrawn
START Midwest	Grand Rapids, Michigan, United States	Recruiting
Columbia University	New York, New York, United States	Recruiting
NYU Langone Health	New York, New York, United States	Recruiting

+ 41 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06128551